Recent trends in upstream bioprocessing and major challenges in …
Sep 17, 2019 · Figure 2: Optimisation areas and parameters in upstream processing. Stable cell lines – a major challenge for upstream development. Establishing the stability of those cell lines being used for antibody production forms an important part of upstream development. Stability conventionally indicates the antibody- production capability of cells.
Improving treatments for rheumatoid arthritis patients - Drug …
Feb 7, 2024 · Treating arthritic mice with RvT4 reduced blood vessel inflammation by reprogramming macrophages to release stored lipids. These lipids stopped the macrophage from doing their normal work of clearing dead cells and reducing localised inflammation in blood vessels. Once freed of their lipid burden, the macrophages could move and work much more ...
Brain organoids: a fascinating and powerful tool for drug discovery
Jul 5, 2024 · Building three-dimensional models in the lab. Brain organoids are three-dimensional (3D) multicellular structures derived from the differentiation of human pluripotent stem cells (hPSCs), including induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs), under specific in vitro neuronal induction conditions, using specific ...
Five recent cell and gene therapy discoveries - Drug Target Review
Dec 27, 2022 · Study uncovers relationship between T cells and CD4. Researchers from the University of Arizona Health Sciences, US, have also found new developments in CAR T-cell therapy. The team discovered that CD4 plays a more active role in regulating T-cell receptor signalling. The CD4 molecule is found on the surface of many T cells and has historically ...
Hit-to-lead in drug discovery - Drug Target Review
Sep 4, 2016 · Therefore, a new process was developed in drug discovery termed hit-to-lead (H2L), or more fully, hit series-to-lead optimisation. H2L, which explores the chemistry and biology of hits to eliminate dead-end structures and provides improvements to the remaining hit series so that development time and costs are saved, is now a key process in drug ...
Sanofi acquires Translate Bio for mRNA therapeutic development
Sep 24, 2021 · Sanofi acquired all outstanding shares of Translate Bio for $38 per share in cash, representing a total equity value of approximately $3.2 billion on a fully diluted basis. Translate Bio is an mRNA therapeutics company developing a new class of medicines to treat or prevent debilitating and life-threatening diseases.
Exploring alternatives to animal testing in drug discovery
Jul 6, 2023 · History behind animal testing. In December 2022, the US Government approved the ground-breaking US Food and Drug Association (FDA) Modernization Act 2.0, allowing researchers to use “certain alternatives to animal testing, including cell-based assays and computer models, to obtain an exemption from the FDA to investigate the safety and effectiveness of a drug.” 3 Furthermore, the act ...
Immuno-oncology innovations redefining cancer treatment in 2024
Jan 23, 2024 · In addition, 2023 brought new approvals for bi-specific T cell engagers, demonstrating impressive responses in haematological cancers, fuelling interest in this way of activating T cells to kill cancer cells. We anticipate this area to grow, especially cancer vaccines, with important read-outs expected across various cancer types in 2024.
Developing an effective vaccine for herpes simplex virus
Feb 13, 2024 · Co-corresponding author Dr David Leib, chair and professor of microbiology and immunology at Geisel, explained: “Despite three decades of trying, the scientific community has been unable to develop an effective vaccine against herpes, and I think the main issue has been that we haven’t fully understood what we need, in terms of antibodies ...
TPD: turning undruggable targets into druggable targets
Jul 6, 2023 · Using TPD to make undruggable targets druggable involves the use of small molecules known as proteolysis-targeting chimeras to selectively degrade specific proteins within a cell, resulting in the modulation of downstream signalling pathways. 3 Protein-protein interactions (PPIs) also play a crucial role in many cellular processes, and have the same modulation of downstream signalling pathways ...